News Image

MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates

Provided By GlobeNewswire

Last update: Nov 13, 2024

LONDON and NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, 2024, and provided a corporate update. The Company also announced that following meetings with the UK Medicines and Healthcare products Regulatory Agency (MHRA), the Company intends to submit a Marketing Authorization Application under exceptional circumstances for AAV-AIPL1 in the United Kingdom without the need for further clinical studies. The Company is also initiating discussions with the FDA around the potential for a similar pathway to approval in the U.S. In addition, MeiraGTx announced that the Offices of Orphan Products Development and Pediatric Therapeutics of the U.S. Food and Drug Administration (FDA) have granted the Company three Rare Pediatric Disease Designations to its AAV8-RK-AIPL1 program, AAV8-RK-BBS10 program, and AAV5-RDH12 program, each for the treatment of inherited retinal diseases.

Read more at globenewswire.com

MEIRAGTX HOLDINGS PLC

NASDAQ:MGTX (7/25/2025, 8:06:42 PM)

After market: 8.37 0 (0%)

8.37

+0.06 (+0.72%)



Find more stocks in the Stock Screener

Follow ChartMill for more